The antibody-drug conjugate showed a higher objective response rate but failed to meet the primary OS endpoint in patients ...

On December 20, 2024, the FDA granted accelerated approval to the combination of encorafenib (Braftovi), cetuximab (Erbitux), ...

Sacituzumab govitecan, currently indicated in triple-negative breast cancer (TNBC), is undergoing evaluation in NSCLC. In ...

The health technology assessment (HTA) agency said that while Trodelvy (sacituzumab govitecan) increases the time people have before their disease worsens and how long they live, "it is too ...

At this year's ASCO congress, news that Trodelvy (sacituzumab govitecan) failed to have a significant impact on overall survival (OS) in this form of breast cancer weighed heavily on Gilead ...

A New York appellate court on Tuesday denied President-elect Donald Trump's bid to halt sentencing set for Friday for his conviction on criminal charges stemming from hush money paid to a porn ...

An Emboldened Trump Talks of Taking Greenland and Panama Canal by Force In a rambling news conference from his private Florida club, President-elect Trump refused to rule out using military force ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...